All parameters have been inspected and approved during the manufacturing process.All parameters have been assessed as meeting specifications.A deformation of the outer housing of the progav was observed through the visual inspection.The progav housing was subsequently measured and confirmed the presence of a deformation.The housing deformation measured at -0.720mm, outside the tolerance of 0+/-0.02mm.A permeabiltiy test has shown that the progav valve is permeable.The progav was tested and is adjustable to all specific pressures.The brake functionality test has shown that the brake function is fully operational and the braking force is within the given tolerances.To test the opening pressure, we used a miethke computer controlled testing apparatus, which simulates a cerebrospinal fluid flow.The test has shown that the progav is not operating within acceptable tolerances.We have dismanteled the valve.Inside the valve we have found a slight build up of substances (likely protein).Based on out investigation, we are unable to substantiate the claim of over-drainage.In contrast, our investigation shows that the valve is operating in an under-drainage state, likely due to the deposits observed inside the valve.As described in our literature, even a small amount of blood or protein can lead to a temporary blockage and could be responsible for the suspected malfunction.This is one of the known, inevitable risks of hc-therapy by shunt implants.
|